These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37560660)

  • 1. Antihypertensive drugs may not delay the symptom progression of Parkinson's disease: A 2-year follow-up study.
    Dong Z; Zuo R; Zhong X; Zhang C; Zou X; Tian Y; Zuo H; Du X; Yu Q; Cheng O
    Heliyon; 2023 Aug; 9(8):e18538. PubMed ID: 37560660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of striatal dopamine transporter binding with motor and non-motor symptoms in early Parkinson's disease.
    Yang Z; Xie Y; Dou K; Yang L; Xie A
    Clin Transl Sci; 2023 Jun; 16(6):1021-1038. PubMed ID: 36915231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression.
    Jackson H; Anzures-Cabrera J; Taylor KI; Pagano G; ;
    Front Neurosci; 2021; 15():765765. PubMed ID: 34966256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
    Pagano G; Boess FG; Taylor KI; Ricci B; Mollenhauer B; Poewe W; Boulay A; Anzures-Cabrera J; Vogt A; Marchesi M; Post A; Nikolcheva T; Kinney GG; Zago WM; Ness DK; Svoboda H; Britschgi M; Ostrowitzki S; Simuni T; Marek K; Koller M; Sevigny J; Doody R; Fontoura P; Umbricht D; Bonni A; ;
    Front Neurol; 2021; 12():705407. PubMed ID: 34659081
    [No Abstract]   [Full Text] [Related]  

  • 5. Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease.
    Pagano G; Yousaf T; Wilson H; Niccolini F; Polychronis S; Chaudhuri KR; Politis M
    Eur J Neurol; 2018 Feb; 25(2):307-312. PubMed ID: 29078029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The glucocerebrosidase mutations and uric acid levels in Parkinson's disease: A 3-years investigation of a potential biomarker".
    Mozafar M; Kazemian S; Hoseini E; Mohammadi M; Alimoghadam R; Shafie M; Mayeli M;
    Clin Park Relat Disord; 2023; 8():100177. PubMed ID: 36590455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocerebrosidase Mutations and Motor Reserve in Parkinson's Disease.
    Chung SJ; Lee PH; Sohn YH; Kim YJ
    J Parkinsons Dis; 2021; 11(4):1715-1724. PubMed ID: 34459414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.
    Fiorenzato E; Antonini A; Bisiacchi P; Weis L; Biundo R
    Mov Disord; 2021 Oct; 36(10):2303-2313. PubMed ID: 34124799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relations of clinical symptoms with dopamine transporter imaging in drug-naïve Parkinson's disease.
    Mito Y; Yabe I; Yaguchi H; Sato C; Takei T; Terae S; Tajima Y
    Clin Neurol Neurosurg; 2020 Sep; 196():105960. PubMed ID: 32593043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of peripheral neutrophils and lymphocytes in early untreated Parkinson's disease: an 8-year follow-up study.
    Kim R; Kang N; Byun K; Park K; Jun JS
    J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1040-1046. PubMed ID: 37451695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.
    Chahine LM; Siderowf A; Barnes J; Seedorff N; Caspell-Garcia C; Simuni T; Coffey CS; Galasko D; Mollenhauer B; Arnedo V; Daegele N; Frasier M; Tanner C; Kieburtz K; Marek K;
    J Parkinsons Dis; 2019; 9(4):665-679. PubMed ID: 31450510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
    Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
    J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study on the Clinical Features of Parkinson's Disease With Probable Rapid Eye Movement Sleep Behavior Disorder.
    Long K; Wan C; Xiang Y; Liu J; Xu Q; Sun Q; Wang Z; Tian Y; Fang L; Yang Y; Yan X; Tang B; Guo J
    Front Neurol; 2020; 11():979. PubMed ID: 33041969
    [No Abstract]   [Full Text] [Related]  

  • 18. The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study.
    Stewart CB; Ledingham D; Foster VK; Anderson KN; Sathyanarayana S; Galley D; Pavese N; Pasquini J
    Front Neurol; 2023; 14():1155669. PubMed ID: 37122303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal DAT changes measured with [
    Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
    Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
    Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.